The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
Quick Facts
What This Study Found
Aprepitant shows a broad-spectrum anticancer effect against many tumor types.
Key Numbers
How They Did This
This is a review article summarizing existing research on NK-1R antagonists and their potential as anticancer drugs.
Why This Research Matters
Repurposing Aprepitant could provide a new strategy for cancer treatment, potentially improving patient quality of life. This approach may lead to more effective therapies for various cancers.
What This Study Doesn't Tell Us
As a review, it does not present original experimental data; further clinical trials are needed to validate findings.
Trust & Context
- Original Title:
- The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
- Published In:
- International journal of molecular sciences, 24(21) (2023)
- Authors:
- Coveñas, Rafael(2), Rodríguez, Francisco D, Robinson, Prema, Muñoz, Miguel
- Database ID:
- RPEP-06816
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06816APA
Coveñas, Rafael; Rodríguez, Francisco D; Robinson, Prema; Muñoz, Miguel. (2023). The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.. International journal of molecular sciences, 24(21). https://doi.org/10.3390/ijms242115936
MLA
Coveñas, Rafael, et al. "The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.." International journal of molecular sciences, 2023. https://doi.org/10.3390/ijms242115936
RethinkPeptides
RethinkPeptides Research Database. "The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagon..." RPEP-06816. Retrieved from https://rethinkpeptides.com/research/covenas-2023-the-repurposing-of-nonpeptide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.